NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Tuesday, July 15, 2025 2:49

Description: 2015-Elanco-logo
Telephone: 01256 353131 (24 hr response) Veterinary Technical Services
Release 2.49
MilbeVet tablets for cats
 
Species: Cats
Therapeutic indication: Pharmaceuticals: Endoparasiticides: Anthelmintics for cats
Active ingredient: Milbemycin Oxime, Praziquantel
Product:MilbeVet tablets for cats
Product index: MilbeVet tablets for cats
Incorporating:MilbeVet 4 mg/10 mg film-coated tablets for small cats and kittens
MilbeVet 16 mg/40 mg film-coated tablets for cats
Qualitative and quantitative composition
One tablet contains:
Active substance
MilbeVet 4 mg/10 mg film-coated tablets for small cats and kittens
MilbeVet 16 mg/40 mg film-coated tablets for cats
Milbemycin oxime
4 mg
16 mg
Praziquantel
10 mg
40 mg
For a full list of excipients, see section Pharmaceutical particulars
Pharmaceutical form
Film-coated tablet.
Oblong shaped, reddish to reddish brown, artificial beef flavoured tablet with a score on both sides.
MilbeVet 4 mg/10 mg bears the imprint “BC”, on one side and “NA” on the other.
MilbeVet 16 mg/40 mg bears the imprint “KK”, on one side and “NA” on the other.
Clinical particulars
Target species
Cats.
Indications for use, specifying the target species
Treatment of mixed infections by immature and adult cestodes and nematodes of the following species:
- Cestodes:
Dipylidium caninum
Taenia spp.
Echinococcus multilocularis
- Nematodes:
Ancylostoma tubaeforme
Toxocara cati
Prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.
Contraindications
MilbeVet 4 mg/10 mg: Do not use in cats of less than 6 weeks of age and/or weighing less than 0.5 kg.
MilbeVet 16 mg/40 mg: Do not use in cats weighing less than 2 kg.
Special warnings
In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the cat should be taken into account.
It is recommended to treat all the animals living in the same household concomitantly.
When infection with the cestode D. caninum has been confirmed, concomitant treatment against intermediate hosts, such as fleas and lice, should be discussed with a veterinarian to prevent re-infection.
Special precautions for use
Special precautions for use in animals
As per good veterinary practice, animals should be weighed to ensure accurate dosing.
Ensure cats and kittens weighing between 0.5 kg and ≤2 kg receive the appropriate tablet strength (4 mg MBO/10 mg praziquantel) and the appropriate dose (1/2 or 1 tablet) for the corresponding weight band (1/2 tablet for cats weighing 0.5 to 1 kg; 1 tablet for cats weighing >1 to 2 kg – 1 tablet).
Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.
No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after use.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable.
Adverse reactions (frequency and seriousness)
Very rare (<1 animal / 10,000 animals treated, including isolated reports)
Gastrointestinal signs (such as Diarrhoea, Emesis)1
Hypersensitivity reactions1
Neurological signs (such as Ataxia, Muscle tremors) 1 Systemic signs (such as Lethargy)1
1especially in young cats
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Can be used in breeding cats including pregnant and lactating queens.
Interaction with other medicinal products and other forms of interaction
The concurrent use of the veterinary medicinal product with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the veterinary medicinal product at the recommended dose.
Although not recommended, the concomitant use of the veterinary medicinal product with a spot on containing moxidectin and imidacloprid at recommended dose rates following a single application was well tolerated in one laboratory study in 10 kittens.
The safety and efficacy of the concurrent use have not been investigated in field studies. In the absence of further studies, caution should be taken in the case of concurrent use of the product with any other macrocyclic lactone. Also, no such studies have been performed with reproducing animals.
Amounts to be administered and administration route
Oral use.
To ensure a correct dosage, body weight should be determined as accurately as possible.
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg. The veterinary medicinal product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease.
Depending on the bodyweight of the cat, the practical dosing is as follows:
Weight
Tablets
MilbeVet 4 mg/10 mg film-coated tablets for small cats and kittens
MilbeVet 16 mg/40 mg film-coated tablets for cats
0.5 - 1 kg
1/2 tablet
> 1 - 2 kg
1 tablet
2 - 4 kg
1/2 tablet
> 4 - 8 kg
1 tablet
> 8 - 12 kg
11/2 tablets
The veterinary medicinal product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. The duration of heartworm prevention is one month. For regular prevention of heartworm disease the use of a monosubstance is preferred.
Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of overdose, in addition to signs observed at the recommended dose (see section Adverse reactions), drooling was observed. This sign will usually disappear spontaneously within a day.
Withdrawal period(s)
Not applicable.
Pharmacological particulars
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellants - endectocides
ATC vet Code: QP54AB51 (milbemycin oxime, combinations)
Pharmacodynamic properties
Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.
The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.
Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite.
Pharmacokinetic particulars
In the cat, praziquantel reaches peak plasma concentrations within an hour after oral administration.
The half life of elimination is around 3 hours.
In the dog, there is rapid hepatic biotransformation, principally to monohydroxylated derivatives.
The principal route of elimination in the dog is renal.
After oral administration in the cat, milbemycin oxime reaches peak plasma concentrations within 2 hours. The half life of elimination is around 13 hours (± 9 hours).
In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity.
Pharmaceutical particulars
List of excipients
Core:
Cellulose, microcristalline
Croscarmellose sodium
Povidone
Lactose monohydrate
Silica, colloidal anhydrous
Magnesium stearate
Coat:
Hypromellose
Macrogol
Talc
Artificial beef flavour
MilbeVet 16 mg/40 mg film-coated tablets for cats includes Iron oxide red
Major incompatibilities
Not applicable.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years
Shelf-life after first opening of the immediate packaging: 6 months (half tablet).
Special precautions for storage
Do not store above 25 °C
Keep the blister in the outer carton in order to protect from light
Nature and composition of immediate packaging
PVC/PE/PVdC/aluminium blisters in an outer cardboard box.
Cardboard box with 1 or 2 blisters of 2 film-coated tablets.
Cardboard box with 1, 2, 5 or 10 blisters of 10 film-coated tablets.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
The veterinary medicinal product should not enter water courses as it may be dangerous for fish and other aquatic organisms.
Marketing Authorisation Holder (if different from distributor)
N/A
Marketing Authorisation Number
MilbeVet 4 mg/10 mg film-coated tablets for small cats and kittens: 00879/3024
MilbeVet 16 mg/40 mg film-coated tablets for cats: 00879/3023
Significant changes
Date of the first authorisation or date of renewal
25 March 2021
Date of revision of the text
February 2025
Any other information
This product is marketed for Independent Vetcare Limited
Legal category
Legal category: POM-V
GTIN
GTIN description:MilbeVet 4 mg/10 mg film-coated tablets for small cats and kittens (50 pack)
GTIN:05420036952732
GTIN description:MilbeVet 16 mg/40 mg film-coated tablets for cats (50 pack)
GTIN:05420036952749